A Phase 2 interventional study of tenofovir DF and emtricitabine /tenofovir DF in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 28 sites in 4 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2011-11-01.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 30th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 4th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 2 started in 2006.
This study's enrollment of 106 is close to the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 16th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2006, is one of 15 in phase 2, and was the 10th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
This study explores the efficacy, safety and tolerability of tenofovir DF (TDF) 300 mg once daily monotherapy versus the combination of emtricitabine 200 mg plus tenofovir DF 300 mg (FTC/TDF) once daily in subjects currently being treated with adefovir dipivoxil (Hepsera) for chronic hepatitis B who have persistent viral replication (detectable hepatitis B virus deoxyribonucleic acid [HBV DNA]).
Subjects with confirmed (within 4 weeks) plasma HBV DNA ≥ 400 copies/mL during double blind treatment at Week 24 or any time thereafter have the option of receiving 12 weeks of open-label FTC/TDF which may be continued through the end of the 168-week treatment period if there is a virologic response (HBV DNA \< 400 copies/mL). Alternatively, subjects with confirmed HBV DNA \< 400 copies/mL at or any time after Week 24 of double-blind treatment may continue blinded therapy up to Week 168 at the discretion of the investigator. If, in the investigator's opinion, it is felt that continued blinded treatment beyond 24 weeks in subjects with confirmed HBV DNA ≥ 400 copies/mL is not beneficial, the subject may discontinue the study and begin commercially available HBV therapy rather than initiate open-label FTC/TDF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Active chronic HBV infection with all the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TDF
Drug: tenofovir DF
FTC/TDF
Drug: emtricitabine /tenofovir DF
300 mg tablet, once daily (QD)
Drug pages: Emtricitabine · Tenofovir
emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48
Time frame: 48 weeks
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
Time frame: 48 Weeks
Change From Baseline in log10 Plasma HBV DNA Levels at Week 48
Time frame: 48 Weeks
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48
Time frame: 48 Weeks
Percentage of Participants With Normal ALT at Week 48
ULN for males = 43 U/L; 34 U/L for females
Time frame: 48 Weeks
Percentage of Participants With Normalized ALT at Week 48
Subjects with elevated ALT at baseline that return to normal by Week 48.
Time frame: 48 Weeks
Hepatitis B Early Antigen (HBeAg) Loss at Week 48
Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.
Time frame: 48 Weeks
HBeAg Seroconversion at Week 48
Defined as having negative serum HBeAg and positive serum antibody to HBeAg \[anti-HBe\] for subjects with positive serum HBeAg at baseline.
Time frame: 48 Weeks
HBsAg Loss at Week 48
Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
Time frame: 48 Weeks
Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48
Defined as having negative serum HBsAg and positive serum antibody to HBsAg \[anti-HBs\] for subject with positive serum HBsAg at baseline.
Time frame: 48 Weeks
Change From Baseline in log10 Plasma HBV DNA Levels at Week 168
Time frame: 168 weeks
Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168
Time frame: 168 weeks
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
Time frame: 168 weeks
Percentage of Participants With Normal ALT at Week 168
ULN for males = 43 U/L; ULN for females = 34 U/L
Time frame: 168 weeks
Percentage of Participants With Normalized ALT at Week 168
Subjects with elevated ALT at baseline that return to normal by Week 48.
Time frame: 168 weeks
Hepatitis B Early Antigen (HBeAg) Loss at Week 168
Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.
Time frame: 168 weeks
Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168
Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.
Time frame: 168 weeks
HBsAg Loss at Week 168
Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
Time frame: 168 weeks
Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168
P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.
Time frame: 168 weeks
A total of 106 subjects were randomized (105 of which were subsequently treated) across 28 study centers in the US, Germany, France and Spain between 24 April 2006 and 07 March 2007.
| Milestone | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Started | 53 | 52 |
| Completed | 52 | 50 |
| Not completed | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Started | 52 | 50 |
| Completed | 46 | 44 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Seroconversion | 1 | 0 |
| percentage of participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 48 | 75.5 | 69.2 |
| log10 copies/mL | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Change From Baseline in log10 Plasma HBV DNA Levels at Week 48 | -3.58 ± 1.290 | -3.34 ± 1.753 |
| U/mL | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 48 | -21.6 ± 54.53 | -41.4 ± 151.67 |
| percentage of participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48 | 81.1 | 80.8 |
ULN for males = 43 U/L; 34 U/L for females
| percentage of participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Normal ALT at Week 48 | 66.7 | 73.1 |
Subjects with elevated ALT at baseline that return to normal by Week 48.
| percentage of participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 48 | 40.7 | 61.5 |
Defined as having negative serum HBeAg for subjects with positive HBeAg at baseline.
| participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Hepatitis B Early Antigen (HBeAg) Loss at Week 48 | 3 | 3 |
Defined as having negative serum HBeAg and positive serum antibody to HBeAg \[anti-HBe\] for subjects with positive serum HBeAg at baseline.
| participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| HBeAg Seroconversion at Week 48 | 2 | 3 |
Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
| participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| HBsAg Loss at Week 48 | 1 | 0 |
Defined as having negative serum HBsAg and positive serum antibody to HBsAg \[anti-HBs\] for subject with positive serum HBsAg at baseline.
| participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 48 | 1 | 0 |
| log10 copies/mL | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Change From Baseline in log10 Plasma HBV DNA Levels at Week 168 | -3.79 ± 1.305 | -3.48 ± 1.629 |
| U/mL | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Change From Baseline in Alanine Aminotransferase (ALT) Levels at Week 168 | -26.8 ± 60.23 | -54.5 ± 141.63 |
| Percent of Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168 | 82.4 | 84.0 |
ULN for males = 43 U/L; ULN for females = 34 U/L
| Percent of Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Normal ALT at Week 168 | 74.0 | 74.0 |
Subjects with elevated ALT at baseline that return to normal by Week 48.
| Percent of Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 168 | 68.0 | 70.8 |
Defined as having negative serum HBeAg for subjecst with positive HBeAg at baseline.
| Percent of Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Hepatitis B Early Antigen (HBeAg) Loss at Week 168 | 21.6 | 24.3 |
Defined as having negative serum BHsAg and positive serum antibody to HBsAg (anti-HBs) for subject with positive serum BHsAg at baseline.
| Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Hepatitis B Surface Antigen (HBsAg) Seroconversion at Week 168 | 1 | 0 |
Defined as having negative serum HBsAg for subjects with positive HBsAg at baseline.
| Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| HBsAg Loss at Week 168 | 1 | 0 |
P-values were from a Cochran-Mantel-Haenszel test, controlling for baseline HBeAg status and prior lamivudine use.
| Percent of Participants | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 169 Copies/mL at Week 168 | 80.4 | 78.0 |
Collected over 168 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir DF | — | — | — |
| Emtricitibine/Tenofovir DF | — | — | — |
| Event | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 0/53 | 2/52 |
| AlcoholismPsychiatric disorders | 0/53 | 1/52 |
| AppendicitisInfections and infestations | 0/53 | 1/52 |
| Atrial FibrillationCardiac disorders | 0/53 | 1/52 |
| BartholinitisReproductive system and breast disorders | 0/53 | 1/52 |
| Cerebrovascular AccidentNervous system disorders | 0/53 | 1/52 |
| Chronic SinusitisInfections and infestations | 0/53 | 1/52 |
| Fibroadenoma of BreastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/53 | 1/52 |
| HemiparesisNervous system disorders | 0/53 | 1/52 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/53 | 1/52 |
| Event | Tenofovir DF | Emtricitibine/Tenofovir DF |
|---|---|---|
| NasopharyngitisInfections and infestations | 16/53 | 12/52 |
| HeadacheNervous system disorders | 15/53 | 10/52 |
| Abdominal Pain UpperGastrointestinal disorders | 8/53 | 9/52 |
| FatigueGeneral disorders | 9/53 | 9/52 |
| Back PainMusculoskeletal and connective tissue disorders | 9/53 | 6/52 |
| Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders | 8/53 | 3/52 |
| BronchitisInfections and infestations | 3/53 | 7/52 |
| AstheniaGeneral disorders | 7/53 | 2/52 |
| Abdominal PainGastrointestinal disorders | 5/53 | 5/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/53 | 5/52 |
| Age Continuous(years) | Tenofovir DF | Emtricitibine/Tenofovir DF | Total |
|---|---|---|---|
| Mean | 40 ± 11.4 | 39 ± 10.4 | 39 ± 10.9 |
| Sex: Female, Male(Participants) | Tenofovir DF | Emtricitibine/Tenofovir DF | Total |
|---|---|---|---|
| Female | 15 | 10 | 25 |
| Male | 38 | 42 | 80 |
| Race/Ethnicity, Customized(Participants) | Tenofovir DF | Emtricitibine/Tenofovir DF | Total |
|---|---|---|---|
| Asian | 26 | 18 | 44 |
| Black or African American | 2 | 8 | 10 |
| White | 23 | 21 | 44 |
| Other | 2 | 5 | 7 |
| Previous Lamivudine Experience(participants) | Tenofovir DF | Emtricitibine/Tenofovir DF | Total |
|---|---|---|---|
| Yes | 30 | 31 | 61 |
| No | 23 | 21 | 44 |
| Baseline HBV DNA(log10 copies/mL) | Tenofovir DF | Emtricitibine/Tenofovir DF | Total |
|---|---|---|---|
| Mean | 6.06 ± 1.430 | 5.87 ± 1.779 | 5.97 ± 1.607 |
The record gives a start of Mar 2006, a primary completion of Jan 2008 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tenofovir · Emtricitabine